Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343586 · ClinicalTrials.gov registry record · NA
Blue Light Phototherapy
A NA study of Psoriasis Vulgaris and Grover's Disease, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04343586: Completed NA study of Psoriasis Vulgaris and Grover's Disease, sponsored by Northwestern University.
NCT04343586 is a NA study of Psoriasis Vulgaris and Grover's Disease that has completed, run by Northwestern University. The registered enrollment target is 11 participants, below the 90-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04343586, a NA study of Psoriasis Vulgaris and Grover's Disease, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
Primary Outcome
Demonstrate preliminary skin efficacy as measured by lesion count
Conditions Studied
Interventions
- DEVICE Blue light phototherapy
Study Locations (1)
Illinois
- Northwestern University Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2022-09-22 |
| Phase | NA |
What the finished NCT04343586 record still lists
NCT04343586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 90-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Blue light phototherapy is the first listed.
NCT04343586 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04343586 about?
NCT04343586 is a clinical study titled "Blue Light Phototherapy". This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
What is the current status of trial NCT04343586?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2020-09-01. Estimated completion is 2022-09-22.
What conditions does trial NCT04343586 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris, Grover's Disease.
What interventions are being tested in trial NCT04343586?
The interventions under investigation include: Blue light phototherapy (DEVICE).
Who is sponsoring clinical trial NCT04343586?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343586 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI